Facile and Green Fabrication of Highly Competent Surface-Modified Chlorogenic Acid Silver Nanoparticles: Characterization and Antioxidant and Cancer Chemopreventive Potential.

Abstract

The eco-friendly, cost-effective, and green fabrication of nanoparticles is considered a promising area of nanotechnology. Here, we report on the green synthesis and characterization of bovine serum albumin (BSA)-decorated chlorogenic acid silver nanoparticles (AgNPs-CGA-BSA) and the studies undertaken to verify their plausible antioxidant and antineoplastic effects. High-resolution transmission electron microscopy (HR-TEM), dynamic light scattering, X-ray diffraction, and Fourier transform infrared analyses depict an average mean particle size of ∼96 nm, spherical morphology, and nanocrystalline structure of AgNPs-CGA-BSA. DPPH scavenging and inhibition of lipid peroxidation signify the noticeable in vitro antioxidant potential of the nanoparticles. The in vitro experimental results demonstrate that AgNPs-CGA-BSA shows significant cytotoxicity to Dalton's lymphoma ascites (DLA) cells and generates an enhanced intracellular reactive oxygen species and oxidized glutathione (GSSG) and reduced glutathione (GSH) in DLA cells. Furthermore, mechanism investigation divulges the pivotal role of the downregulated expression of superoxide dismutase (SOD) and catalase (CAT), and these ultimately lead to apoptotic chromatin condensation in AgNPs-CGA-BSA-treated DLA cells. In addition, in vivo experiments reveal an excellent decrease in tumor cell count, an increase in serum GSH and CAT, SOD, and glutathione peroxidase activities, and a decrease in the malondialdehyde (MDA) level in DLA-bearing mice after AgNPs-CGA-BSA treatment. These findings suggest that the newly synthesized biogenic green silver nanoparticles have remarkable in vitro antioxidant and antineoplastic efficacy that triggers cytotoxicity, oxidative stress, and chromatin condensation in DLA cells and in vivo anticancer efficacy that enhances the host antioxidant status, and these might open a new path in T-cell lymphoma therapy.